Reblozyl (luspatercept-aamt) is an erythroid maturation agent used to treat transfusion-related anemia in selected beta-thalassemia and myelodysplastic syndrome populations. The prescribing information describes it as a recombinant fusion protein that reduces Smad2/3 signaling and promotes erythroid maturation. U.S. labeling lists initial approval in 2019.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Bristol Myers Squibb reported fourth quarter and full year 2025 results that beat consensus expectations, with total revenues of $48.3 billion. The company announced FDA acceptance of its new drug application for iberdomide and positive Phase 2 results for Reblozyl.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07331818 |
Luspatercept in Patients Affected With Rare Inherited Anemias |
NOT_YET_RECRUITING | PHASE2 |
